The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Rhinex Relief 50 micrograms/actuation Nasal spray, suspension

50 Mcg/Acutuation Nasal spray, suspension

Rowex LtdPA0711/279/001

Main Information

Trade NameRhinex Relief 50 micrograms/actuation Nasal spray, suspension
Active SubstancesMometasone furoate
Strength50 Mcg/Acutuation
Dosage FormNasal spray, suspension
Licence HolderRowex Ltd
Licence NumberPA0711/279/001

Group Information

ATC CodeR01AD Corticosteroids
R01AD09 mometasone

Status

Authorised/WithdrawnAuthorised
Licence Issued20/07/2018
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceProduct Not Subject to Medical Prescription The following pack sizes are subject to medical prescription which may be renewed: 2 bottles containing 18.0 g nasal spray, suspension, corresponding to 140 sprays each, 3 bottles containing 18.0 g nasal spray, suspension, corresponding to 140 sprays each.
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back